MA53516A1 - Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes. - Google Patents

Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes.

Info

Publication number
MA53516A1
MA53516A1 MA53516A MA53516A MA53516A1 MA 53516 A1 MA53516 A1 MA 53516A1 MA 53516 A MA53516 A MA 53516A MA 53516 A MA53516 A MA 53516A MA 53516 A1 MA53516 A1 MA 53516A1
Authority
MA
Morocco
Prior art keywords
prevention
bronchoconstriction
treatment
allergen
late phase
Prior art date
Application number
MA53516A
Other languages
English (en)
Inventor
Didier Cataldo
Brigitte Evrard
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Publication of MA53516A1 publication Critical patent/MA53516A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une cyclodextrine inhalable destinée à être utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes est divulguée. L'utilisation d'une cyclodextrine dans le traitement et la prévention par inhalation de la bronchoconstriction tardive dans l'asthme allergique est également divulguée.
MA53516A 2020-06-15 2021-06-09 Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes. MA53516A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE202005430 2020-06-15

Publications (1)

Publication Number Publication Date
MA53516A1 true MA53516A1 (fr) 2022-04-29

Family

ID=72521354

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53516A MA53516A1 (fr) 2020-06-15 2021-06-09 Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes.

Country Status (3)

Country Link
US (1) US20210386668A1 (fr)
BE (1) BE1028268B1 (fr)
MA (1) MA53516A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263084A (en) * 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
EP1655034A1 (fr) * 2004-10-10 2006-05-10 Université de Liège Utilisation d'un composé de cyclodextrine pour le traitement et la prévention des maladies inflammatoires bronchiques.
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs

Also Published As

Publication number Publication date
BE1028268B1 (fr) 2021-12-02
US20210386668A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
Zhao et al. Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis
ATE477804T1 (de) Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
Nathan et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate
MA34002B1 (fr) Thérapie antivirale
HUP0303340A2 (hu) Eljárások gyulladásos vagy autoimmun rendellenességek megelőzésére vagy kezelésére integrin alfa-v-béta-3 antagonisták más profilaktikusan vagy terápiásan hatásos ágensekkel kombinált beadásával
US4486450A (en) Method of treating psoriatic skin and composition
NO20051212D0 (no) Ny kombinasjon av glukokortikoider og PDE-4 inhibitorer for behandling av luftveissykdommer, allergiske sykdommer, astma og COPD
MA53516A1 (fr) Cyclodextrine utilisée dans le traitement et la prévention de la bronchoconstriction en phase tardive de l'asthme provoqué par des allergènes.
De Wet et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab
JP2002537245A5 (fr)
De Smet et al. Grip strength in patients with tennis elbow. Influence of elbow position
MA53482B1 (fr) Thérapie d'infections par le papillomavirus humain à haut risque
Chalmers et al. T2 Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis
BE1030002A1 (fr) Compositions inhalables comprenant un complexe de hpbcd et de budesonide ou ciclesonide pour le traitement ou la prevention d'une maladie virale respiratoire
Glassberg et al. Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF)
CALLAWAY et al. Pyogenic infections of skin: etiologic factor in acute glomerulonephritis of children
Gargi et al. Tourniquet application in snake bite: are we aweare
Finnigan et al. Efficacy and Tolerability of AXA1125, an Endogenous Metabolic Modulator Composition, in Fatigue-predominant Long COVID: A Randomized, Double-blind, Placebo-controlled Study
Spangler Pyoderma gangrenosum in a patient with psoriatic arthritis.
Thokchom et al. Pyoderma gangrenosum with Takayasu's arteritis: A rare association
Abrol et al. Knowledge, attitude, and behavior in the prescription of topical steroid for dermatological disorders among medical practitioners
Aozasa et al. Case of oral lichen planus treated successfully with irsogladine maleate
EP0095512B1 (fr) Composition antipsoriatique
AlEid e02 Cutaneous polyarteritis nodosa
Nisar e03 ACTH reborn: modernising the evidence